New England Journal of Medicine· 2020Q1

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt, Michael Szarek, Philippe Gabríel Steg, Christopher P. Cannon et al.

1,838citations
Q1SCImago
2020year

Short summary

Sotagliflozin significantly reduced the composite endpoint of cardiovascular death, heart failure hospitalizations, and urgent heart failure visits by 33% (HR 0.67) in patients with type 2 diabetes recently hospitalized for worsening heart failure.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine